News coverage about Second Sight Medical Products (NASDAQ:EYES) has been trending positive recently, according to Accern Sentiment. Accern identifies negative and positive news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Second Sight Medical Products earned a media sentiment score of 0.27 on Accern’s scale. Accern also assigned press coverage about the medical device company an impact score of 46.2229968661264 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Here are some of the news stories that may have effected Accern Sentiment’s analysis:
- Analysts Offer Insights on Healthcare Companies: Second Sight Medical Products (NASDAQ: EYES), Eyegate … - Analyst Ratings (analystratings.com)
- Technical Story: Second Sight Medical Products, Inc. (EYES) stands -7.01% away from 50 SMA - Voice Of Analysts (analystsbuzz.com)
- What Are the Ichimoku Levels Revealing For Second Sight Medical Products Inc (EYES)? - Evergreen Caller (evergreencaller.com)
- Chartists Place Second Sight Medical Products Inc (EYES) on Notice: Technical Update - Sheridan Daily (sheridandaily.com)
- What Story Are The Numbers Telling For Second Sight Medical Products Inc (EYES) - Financial News Review (finnewsreview.com)
EYES has been the subject of a number of analyst reports. HC Wainwright set a $5.00 price target on Second Sight Medical Products and gave the company a “buy” rating in a report on Tuesday. Zacks Investment Research downgraded Second Sight Medical Products from a “buy” rating to a “hold” rating in a report on Thursday, May 11th.
Shares of Second Sight Medical Products (EYES) traded up 0.88% during mid-day trading on Tuesday, reaching $1.14. The company’s stock had a trading volume of 117,870 shares. Second Sight Medical Products has a 12 month low of $1.06 and a 12 month high of $4.25. The company has a 50 day moving average price of $1.25 and a 200 day moving average price of $1.33. The stock’s market capitalization is $64.26 million.
Second Sight Medical Products (NASDAQ:EYES) last issued its quarterly earnings results on Tuesday, August 1st. The medical device company reported ($0.13) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.14) by $0.01. The company had revenue of $2.24 million for the quarter, compared to the consensus estimate of $1.43 million. Second Sight Medical Products had a negative return on equity of 127.16% and a negative net margin of 306.04%. The firm’s revenue was up 124.0% compared to the same quarter last year. During the same period last year, the business posted ($0.17) earnings per share. On average, equities research analysts anticipate that Second Sight Medical Products will post ($0.52) earnings per share for the current fiscal year.
About Second Sight Medical Products
Second Sight Medical Products, Inc is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight.
Receive News & Ratings for Second Sight Medical Products Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products Inc and related companies with MarketBeat.com's FREE daily email newsletter.
